Abstract

We attempt to investigate and study the effect of azithromycin combined with budesonide treatment regimen on inflammatory factors and therapeutic effect in patients with Mycoplasma pneumonia. 100 patients with Mycoplasma pneumonia were selected in a hospital from January 2020 to December 2022 as the investigation subjects and divided them into two parts according to their admission time, control group consists of 50 patients whose treatment regimen was azithromycin orally combined with acetyl cysteine nebulization, and observation group consists of 50 patients whose treatment regimen was azithromycin orally combined with budesonide and acetyl cysteine nebulization. Detected the serum inflammatory factors and their related index values, the clinical efficacy and the occurrence of adverse reactions during the treatment period of the children with Mycoplasma pneumonia. The results showed that the serum inflammatory factor levels of the children in the observation group improved compared with those in the control group (p<0.05). Observation group possessed higher total clinical efficacy than control group (p<0.05). Observation group possessed lower incidence of adverse reactions than control group (p<0.05). The treatment regimen of azithromycin and budesonide combined with acetyl cysteine in patients with Mycoplasma pneumonia can achieve good clinical efficacy and good improvement in serum inflammatory factors, and there is no significant increase in adverse effects and high safety, which makes this treatment regimen suitable for promotion in patients with Mycoplasma pneumonia.